226 related articles for article (PubMed ID: 19768880)
21. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
22. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
23. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Monnier AM
Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
[TBL] [Abstract][Full Text] [Related]
24. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
Wheler J; Johnson M; Seidman A
Semin Oncol; 2006 Dec; 33(6):672-80. PubMed ID: 17145347
[TBL] [Abstract][Full Text] [Related]
26. Is long-term adjuvant treatment of breast cancer with anastrozole indicated?
Doggrell SA
Expert Opin Pharmacother; 2008 Jun; 9(9):1619-22. PubMed ID: 18518790
[TBL] [Abstract][Full Text] [Related]
27. Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity.
Chlebowski RT; Haque R; Hedlin H; Col N; Paskett E; Manson JE; Kubo JT; Johnson KC; Wactawski-Wende J; Pan K; Anderson G
Breast Cancer Res Treat; 2015 Dec; 154(3):609-16. PubMed ID: 26602222
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials.
Qian X; Li Z; Ruan G; Tu C; Ding W
Breast Cancer Res Treat; 2020 Jan; 179(2):275-285. PubMed ID: 31606823
[TBL] [Abstract][Full Text] [Related]
29. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
Chlebowski RT
Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():25-34. PubMed ID: 19101792
[TBL] [Abstract][Full Text] [Related]
30. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.
Buzdar AU
Oncologist; 2003; 8(4):335-41. PubMed ID: 12897330
[TBL] [Abstract][Full Text] [Related]
31. Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting.
Morales L; Neven P; Paridaens R
Curr Opin Oncol; 2005 Nov; 17(6):559-65. PubMed ID: 16224233
[TBL] [Abstract][Full Text] [Related]
32. Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy.
Kaufmann M; Rody A
J Cancer Res Clin Oncol; 2005 Aug; 131(8):487-94. PubMed ID: 15915367
[TBL] [Abstract][Full Text] [Related]
33. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Dunn C; Keam SJ
Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
[TBL] [Abstract][Full Text] [Related]
34. Aromatase inhibitors as adjuvant therapy in breast cancer.
Visvanathan K; Davidson NE
Oncology (Williston Park); 2003 Mar; 17(3):335-42, 347; discussion 347-50, 354. PubMed ID: 12661266
[TBL] [Abstract][Full Text] [Related]
35. The evolving role of aromatase inhibitors in adjuvant breast cancer therapy.
Henderson IC; Piccart-Gebhart MJ
Clin Breast Cancer; 2005 Aug; 6(3):206-15. PubMed ID: 16137430
[TBL] [Abstract][Full Text] [Related]
36. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
Winer EP; Hudis C; Burstein HJ; Chlebowski RT; Ingle JN; Edge SB; Mamounas EP; Gralow J; Goldstein LJ; Pritchard KI; Braun S; Cobleigh MA; Langer AS; Perotti J; Powles TJ; Whelan TJ; Browman GP
J Clin Oncol; 2002 Aug; 20(15):3317-27. PubMed ID: 12149306
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant endocrine therapy for early breast cancer.
Andreetta C; Smith I
Cancer Lett; 2007 Jun; 251(1):17-27. PubMed ID: 17150303
[TBL] [Abstract][Full Text] [Related]
38. A practical overview of aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer.
Younus J; Vandenberg TA
Bull Cancer; 2005 Apr; 92(4):E39-44. PubMed ID: 15888383
[TBL] [Abstract][Full Text] [Related]
39. Reducing early recurrence with adjuvant aromatase inhibitors: what is the evidence?
Dixon JM
Breast; 2008 Aug; 17(4):353-60. PubMed ID: 18490163
[TBL] [Abstract][Full Text] [Related]
40. Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
Aapro MS; Forbes JF
Breast Cancer Res Treat; 2003; 80 Suppl 1():S3-11; discussion S13-8. PubMed ID: 14535530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]